Reply to Letter to the Editor: “Anticoagulation in Real-Life Patients with Atrial Fibrillation: Impact of Renal Disease”

The renal elimination rate of nonvitamin K antagonist anticoagulants (NOACs) can vary within a wide range. Around 80% of dabigatran, 50% of edoxaban, 35% of rivaroxaban, and 27% of apixaban can be eliminated by kidney. 1 Renal function should be monitored at least once a year in all patients using NOACs. 2 Rivaroxaban, apixaban

[1]  Tuncay Güzel,et al.  Oral Anticoagulant Use and Long-Term Follow-Up Results in Patients with Non-valvular Atrial Fibrillation in Turkey AFTER-2 Study , 2022, Anatolian journal of cardiology.

[2]  R. de Caterina,et al.  Should We Continue Assessing Glomerular Filtration Rate with the Cockroft–Gault Formula in NOAC-Treated Patients? The Magnitude of the Problem , 2020, Journal of clinical medicine.

[3]  T. Potpara,et al.  Bleeding in anticoagulated patients with atrial fibrillation: practical considerations. , 2020, Polish archives of internal medicine.

[4]  Hugh Calkins,et al.  2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2019, Heart rhythm.

[5]  A. Camm,et al.  The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. , 2018, European heart journal.

[6]  G. Lip,et al.  Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report , 2012, Chest.

[7]  G. Lip,et al.  Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study , 2017, British Medical Journal.

[8]  Ulrich Schotten,et al.  2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS. , 2017, Revista espanola de cardiologia.

[9]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[10]  E. Kalaycıoğlu,et al.  ReAl-life Multicenter Survey Evaluating Stroke prevention strategies in non-valvular atrial fibrillation (RAMSES study) , 2016, Anatolian journal of cardiology.

[11]  Z. Harel,et al.  Comparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD. , 2014, Journal of the American Society of Nephrology : JASN.

[12]  E. Antman,et al.  Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.

[13]  D. Atar,et al.  Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[14]  Jun Zhu,et al.  Apixaban in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[15]  R. Troughton,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[16]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[17]  G. Breithardt,et al.  Dilemmas in the management of atrial fibrillation in chronic kidney disease. , 2009, Journal of the American Society of Nephrology : JASN.

[18]  G. Lip,et al.  Antithrombotic therapy for atrial fibrillation , 2002, BMJ : British Medical Journal.